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Expression of p53, Bcl2 and Bax in cisplatinminduced
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Summary We examined the sensitivity for cisplatin-induced apoptosis in a panel of four testicular germ cell tumour (TGCT) cell lines and
monitored the cellular expression of the apoptosis-related proteins p53, Bcl-2 and Bax. Three of four TGCT cell lines (NT2, NCCIT and S2)
were hypersensitive for cisplatin-induced apoptosis, while the TGCT cell line 2102 EP appeared to be resistant for cisplatin-induced
apoptosis, even at relatively high drug concentrations (12.5 IIM). For all four cell lines, the induction of apoptosis by cisplatin correlated with
drug sensitivity in the MTT assay. The differences in chemosensitivity and induction of apoptosis could not be attributed to differences in
cellular platinum accumulation, DNA platination or platinum-DNA adduct removal. We next analysed the relationship between p53 status and
cisplatin-induced up-regulation of p53, and the susceptibility to cisplatin-induced apoptosis. Wild-type p53 containing NT2 and 2102 EP cells
showed p53 up-regulation upon drug treatment, and NCCIT (mutant p53) and S2 (no p53 protein) cells did not. Consistently, the increase in
wild-type p53 protein in NT2 and 2102 EP cells led to an increase in mRNA level of the p53downstream gene p21/WA/F/C/P, whereas mutant
p53-containing NCCIT cells and p53-non-expressing S2 cells could not transactivate this p53-responsive gene. As NT2, NCCIT and S2 were
readily triggered into apoptosis, while 2102 EP cells failed to undergo cisplatin-induced apoptosis, our data suggest that the presence of wild-
type and/or transactivation-competent p53 might not be an absolute prerequisite for efficient induction of apoptosis in TGCT cell lines. Also
endogenous levels of Bcl-2 and Bax expression did not correlate with cisplatin-induced apoptosis. In addition, the endogenous Bcl-2 and Bax
expression was not affected by cisplatin treatment. The present study suggests that, at least in our panel of TGCT cell lines, hypersensitivity
for cisplatin-induced apoptosis might not be necessarily correlated with the presence of wild-type p53 and is probably not associated with
Bcl-2 and Bax expression.
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Testicular germ cell tumours (TGCTs) represent one of the few
tumour types that are curable by chemo- and radiotherapy, with an
overall cure rate of about 80% (Einhom, 1990). As yet, the nature
ofthe exceptional sensitivity oftesticular tumours to cytoreductive
therapy has not been defined. As it has now been established that
ionizing radiation and a large variety of anti-cancer drugs exert
their cytotoxic action through the induction of apoptosis, and that
inhibition of the apoptotic pathway may lead to cytotoxic drug
resistance (Dive and Hickman, 1991; Lotem and Sachs, 1993;
Kerr et al, 1994), one might speculate that TGCTs are hypersensi-
tive to treatment-induced apoptosis.
It has been demonstrated that the product of the p53 tumour-
suppressor gene plays a pivotal role in the sensitivity of tumour
cells to chemotherapy- or radiation-induced apoptosis (Clarke et
al, 1993; Lowe et al, 1993; Fisher, 1994; Harris, 1996). Functional
inactivation of p53 by mutations or interactions with cellular or
viral proteins can, in some circumstances, lead to resistance to
genotoxic agents commonly used in anti-cancer therapies. Indeed,
the apoptotic response to chemotherapeutic agents was diminished
in the absence of p53, as shown for cells of transgenic mice
homozygous forp53 null alleles (Lotem and Sachs, 1993; Lowe et
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al, 1993). In addition, in vitro studies show that mutations in the
p53 gene may render cells resistant to induction of apoptosis by
ionizing radiation and chemotherapeutics (Fan et al, 1994).
Another important regulator of apoptosis is the product of the
Bcl-2 gene, which was first identified at the t(14;18) translocation
in human follicular lymphoma cells (Korsmeyer, 1992). Recently,
several cellular and viral homologues of Bcl-2 have been identi-
fied that belong to a rapidly expanding Bcl-2 protein family (Reed
et al, 1996). The Bcl-2 family proteins are involved in the control
of apoptosis in a range of different cell types and can either func-
tion as inhibitors (e.g. Bcl-2, Bcl-xL, Mcl-1, Al and Bag) or
promoters (e.g. Bax, Bcl-xs, Bad and Bak) of cell death (Oltvai
and Korsmeyer, 1994; Reed et al, 1996). Some of these proteins
physically interact with each other and form homo- and
heterodimers (e.g. Bcl-2/Bcl-2, Bcl-2/Bax and Bax/Bax). It was
proposed that Bax homodimers promote apoptosis and that
the Bax-mediated cell death is counteracted by Bcl-2/Bax
heterodimerization (Oltvai and Korsmeyer, 1994). Recent reports
have demonstrated that wt p53 can positively regulate Bax gene
expression and is involved in negative regulation of Bcl-2 gene
expression (Miyashita et al, 1994). Therefore, the p53 status may
determine the vulnerability of cells to apoptotic stimuli by
modulation ofthe Bcl-2/Bax rheostat (Zhan et al, 1994).
Mutations in the p53 gene appeared to be one of the most
frequently occurring genetic aberrations in human cancer.
However, the vast majority of TGCTs has no mutations in their
p53 alleles (Peng et al, 1993), and this lack of p53 mutations has
been implicated in the high response rate of this neoplasm to
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chemotherapy (Cresta et al, 1996). Several human TGCT cell lines
have been established that retained their relative sensitivity to
cytotoxic agents, suggesting that these cell lines are representative
models for chemosensitive TGCT. In the present study, we investi-
gated the expression of p53, Bcl-2 and Bax in drug-induced
apoptosis in a panel of well-defined TGCT cell lines. Our data
suggest that, at least in our panel ofTGCT cell lines, the cisplatin-
induced apoptosis can not be directly correlated with p53 status
and is probably not regulated by the Bcl-2/Bax rheostat.
MATERIALS AND METHODS
Cells and cell culture
The TGCT cell lines used in this study were NT2 (ATCC CRL-
1973), 2102 EP (Wang et al, 1981), S2 (a gift from A von Keitz,
Marburg, Germany) and NCCIT (Damjanov et al, 1993). The in
vitro doubling times of these cell lines are approximately 33, 32,
31 and 25 h, and the distribution over the different cell cycle
phases (GI, S, G2/M) showed no significant differences. The cell
lines were grown as monolayers and maintained in HEPES-
buffered RPMI 1640 supplemented with 10% fetal calf serum
(FCS) (Gibco, Life Technologies, Paisley, UK), 100 IU ml-' peni-
cillin (Sigma-Aldrich, Zwijndrecht, The Netherlands), 100 ,tg ml-'
streptomycin (Sigma) and 2 mM L-glutamine (Gibco BRL).
MTT assay
The MTT colorimetric assay (Carmichael et al, 1987) was used to
quantitate the chemosensitivity of the cell lines to cisplatin (cis-
diamminedichloroplatinum II). Briefly, cells were harvested
during the exponential growth phase and seeded into 96-well
(3000 cells per well) tissue culture plates (Microtest III, Falcon
3072, Beckton Dickinson Labware, NJ, USA). Serial dilutions of
cisplatin (Platosin, Pharmachemie BV, Haarlem, The Netherlands)
were added to quadruplicate wells, and the cells were cultured in
the presence of the drug for an additional 4 days. The IC,, values,
defined as the cisplatin concentration that reduced the absorbance
by 90%, were estimated graphically from the concentration-
response curves as described elsewhere (Carmichael et al, 1987).
Intracellular platinum accumulation and DNA
platination
Triplicate 75-cm2 tissue culture flasks with exponentially growing
cells were exposed to cisplatin (100 tM, 2 h). At the end of the
incubation period the cells were washed to remove free cisplatin,
trypsinized, washed with ice-cold phosphate-buffered saline
(PBS) (3 x 10 ml) and lysed on ice in 500 gl of0.2% (w/v) Triton-
X-100 (Sigma)/H2O. The protein concentration of the lysates
was determined using a Bio-Rad protein assay kit (Bio-Rad
Laboratories, Veenendaal, The Netherlands). Total platinum (Pt)
content was determined in duplicate by atomic absorption
spectrometry (AAS) using a flameless Perkin-Elmer 4110 ZL
spectrometer. Intracellular Pt levels were expressed as ,ug of Pt
per mg ofprotein (,ug Pt mg-' protein).
To determine Pt levels bound to DNA, cisplatin-treated cells
were washed with PBS (3 x 20 ml) and lysed in the tissue culture
flasks at 37°C for 16 h with 10 ml of DNA lysis buffer containing
0.5% sodium dodecyl sulphate (SDS), 10 mM Tris-HCl (pH 8.2),
400 mm sodium chloride, 2 mM EDTA and 0.5 mg ml-] proteinase
K (Boehringer, Mannheim, Germany). The salting-out procedure
for extracting DNA (Miller et al, 1988) was used to prepare
genomic DNA. Subsequently, the DNA samples were sonicated at
4°C for 1 h, and DNA content (absorbance at 260 nm) and Pt-DNA
adducts were determined by AAS. The DNA platination levels
were expressed as pg of Pt per ,ug ofDNA (pg Pt ug-' DNA).
Microscopical detection of cisplatin-induced apoptosis
Cells from exponential phase cultures were seeded at a density of
106 cells per 75 cm2 in tissue culture flasks and 24 h later exposed
to cisplatin (1.6-12.5 gM). After drug incubation (2 h at 37°C),
cells were washed with culture medium and further cultured in
drug-free medium for 6-96 h. Apoptotic cells were recognized by
condensed nuclear chromatin, fragmented nuclei and the appear-
ance of apoptotic bodies. The morphological changes were visual-
ized by Hoechst 33342 (0.5 gg ml-') and propidium iodide (PI,
2.5 gg ml-') both obtained from Calbiochem, La Jolla, CA, USA.
After the drug-free incubation period, the cells were viewed
under a fluorescence microscope (Zeiss) and, for quantitation of
apoptosis, at least 200 cells were scored.
Western blot analysis
For Western blot analysis, both detached and adherent cisplatin-
treated cells were combined, washed with ice-cold PBS
(3 x 10 ml) and lysed in lysis buffer (10 mM Tris-HCl, pH 7.4, 150
mm sodium chloride, 5 mM EDTA and 1% Triton-X-100) supple-
mented with the protease inhibitors phenylmethylsulphonyl fluo-
ride (1 mM PMSF; Boehringer), aprotinin (0.23 units ml-'; Sigma)
and leupeptin (10 jiM; Boehringer). Samples containing 20 jg
of protein in loading buffer (50 mM Tris-HCl, pH 6.8, 0.1N%
bromophenol blue, 2% sodium dodecyl sulphate (SDS), 10%
glycerol, 100 mM dithioerythritol) were boiled for 3 min,
subjected to SDS-PAGE (12%) and transferred to Immobilon-P
transfer membrane (Millipore). Membranes were blocked with 5%
(w/v) non-fat dry milk (Protifar, Nutricia, Zoetermeer, The
Netherlands) in TBS (50 mM Tris, pH 7.5, 150 mM sodium chlo-
ride) and incubated (overnight at 4°C) with specific monoclonal
(MAb) or polyclonal antibody (PAb) diluted in TBS/2% Tween
20. Bcl-2-specific mouse IgG, MAb (100), p53-specific mouse
IgG2a MAb (DO-1) and Bax-specific rabbit IgG PAb (N-20) were
purchased from Santa Cruz Biotechnology, CA, USA, and used at
a dilution of 1:5000 (Bax) or 1:1000 (p53 and Bcl-2). Poly(ADP-
ribose) polymerase (PARP)-specific mouse MAb (C-2-10) and
Bax-specific mouse IgG2b MAb were purchased, respectively,
from BIOMOL, Plymouth Meeting, PA and Immunotech, Coulter
Company, Mijdrecht, The Netherlands, and used at a dilution of
1:5000. Immunological complexes were visualized by enhanced
chemiluminescence (Pierce, Europe BV) using horseradish
peroxidase-conjugated goat anti-mouse or goat anti-rabbit IgG
(1:4000; Santa Cruz Biotechnology).
Isolation and sequencing of p53 cDNAs
In order to establish the p53 DNA sequences of the four studied
TGCT cell lines, total cellular RNA was reverse transcribed using
antisense p53 primers, and single-stranded p53 cDNA was subse-
quently amplified by the polymerase chain reaction using four
different sets of p53-specific primers. The four p53 cDNA frag-
ments (fragment 1: nt 137-486 corresponding to aa 1 117; fragment
British Journal of Cancer (1998) 77(10), 1562-1567 . Cancer Research Campaign 19981564 H Burgeretal
+,COGlTI I
.-S2
. 21.2 EP .0
Figure 1 Cisplatin-induced apoptosis in TGCT cell lines. For the time-course (A) cells were exposed to cisplatin (12.5 gM) for 2 h and apoptosis was
quantitated at the indicated time points after treatment. To establish the dose-effect relationship for the different TGCT cell lines (B), cells were incubated with
the indicated doses of cisplatin and apoptosis was quantitated 72 h after treatment. Typical morphological changes associated with apoptosis were examined by
Hoechst/PI staining and visualized by fluorescence microscopy analysis, and the number of apoptotic cells was counted
Table 1 Characterization of cisplatin sensitivity and induction of apoptosis in TGCT cell lines
Apoptosis
Cell line Pt accumulationa DNA platinationa Hoechst/Plb PARPc p53d p530 p21'
(ng Pt mg-' protein) (pg Pt gg-1 DNA) (status)
NT2 85.5±8.5 76.3±8.2 82±6 + wt/wt 1 I
NCCIT 117.3+ 1.8 98.4±9.7 80±8 + mt/- =
S2 193.6±9.8 132.9±8.9 75±6 + wt/wt -
2102 EP 84.8±3.7 79.2±6.7 10+4 - wt/wt T I
aTotal intracellular Pt concentration (mean ± s.d.) and total amount of Pt bound to DNA were measured by AAS after 2 h exposure of the cells to 100gM of
cisplatin. The Pt accumulation and Pt/DNA adducts data were derived from three independent experiments. bApoptosis was determined at t= 72 h after drug
treatment and data from four independent experiments are shown and expressed as percentages (mean ± s.d.). The apoptotic changes in cell morphology were
microscopically examined (at least 200 cells) after Hoechst/PI staining. cThe presence (+) and absence (-) of cisplatin-induced proteolytic cleavage of PARP
was determined at t = 48 h after cisplatin treatment (12.5 gM, 2 h) by Western blot analysis with C-2-10, a PARP-specific MAb. dThe p53gene status of the
TGCT cell lines was determined by p53cDNA sequencing and revealed that NCCIT cells are hemizygous for p53 containing one mutated allele carrying 1-bp
deletion. aExpression of the p53 protein was monitored by Western blot analysis with DO1, a p53-specific MAb. The effect of cisplatin (12.5gM) on p53
expression (up-regulation, T; no perturbation, =; undetectable, -) was determined in the TGCT cell lines at t= 48 h after treatment. 'The p2lMWAF/CIP mRNA
expression level was determined by Northern blot analysis. The effect of cisplatin (12.5gM) on p21 mRNA expression level (up-regulation, T; no perturbation,
undetectable, -) was determined 6 h after drug treatment.
2: nt411-762 corresponding to aa 93-202; fragment 3: nt 694-1029
corresponding to aa 188-291; fragment 4: nt 993-1317 corre-
sponding to aa 287-387) were completely sequenced according to
the chain-termination method, and p53 nt and aa positions were as
described by Zakut-Houri et al (1985).
RESULTS AND DISCUSSION
Cisplatin-induced apoptosis
TGCTs represent one ofthe few types of cancer that are curable by
cisplatin-containing chemotherapy and, consistently, most TGCT
cell lines display an unusually high sensitivity to cytotoxic agents
(Masters et al, 1993; Huddart et al, 1995, Cresta et al, 1996).
However, analysis of potentially relevant parameters, including
cellular detoxification mechanisms (e.g. the glutathione and the
metallothionein systems), Pt accumulation, DNA platination and
repair, and topoisomerase activity have not been able, so far, to
elucidate the nature of this exceptional sensitivity (Sark et al,
1995). In the present study, we investigated the susceptibility of a
panel of four TGCT cell lines to cisplatin-induced apoptosis and
evaluated the role ofp53, Bcl-2 and Bax. Within this panel ofcell
lines, the difference in sensitivity for cisplatin in the MTT antipro-
liferation assay, as estimated by the IC90 values, was about four-
fold, and we first analysed whether the differences in IC90 values
correlated with induction of apoptosis. The cell lines were
incubated for 2 h with cisplatin, and apoptosis was assayed by
morphology and by proteolytic cleavage of PARP, a nuclear
enzyme involved in DNA repair, which is generally regarded as an
early marker ofchemotherapy-induced apoptosis (Kaufmann et al,
1993). The time course of apoptosis induction showed that, 48-
72 h after cisplatin treatment (12.5 gM), the vast majority of
NT2, NCCIT and S2 cells had an apoptotic appearance as judged
by morphological changes, such as chromatin condensation,
nuclear fragmentation and the appearance of apoptotic bodies
(Figure IA). In contrast, only about 10% ofcisplatin-treated 2102
EP cells exhibited apoptotic nuclei. In addition, the time course of
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Figure 2 (A) Western blot analysis of cisplatin-induced cleavage of PARP in
NCCIT and 2102 EP, two representative TGCT cell lines. Cells were
incubated in the absence (-) and presence (+) of drug (12.5 gM of cisplatin,
2 h at 370C). At t= 48 h after treatment, the integrity of PARP was monitored
by immunoblotting. The results shown of one experiment are typical of three
independent replicates. (B) Western blot analysis of p53, Bcl-2 and Bax
protein levels in TGCT cell lines. Cells were incubated in the absence (-) and
presence (+) of cisplatin, and at t= 48 h after drug treatment the p53, Bcl-2
and Bax protein levels were monitored by immunoblotting. The effect of
cisplatin treatment (3.1-12.5 gM, 2 h at 370C) on endogenous p53, Bcl-2 and
Bax protein levels was examined and a representative experiment with
12.5gM of cisplatin is shown. Coomassie staining of duplicate blots showed
that equivalent amounts of protein were present in all samples analysed. The
different TGCT cell lines are indicated. Molecular weight markers are
indicated in kilodaltons (kDa) at the left and the arrows indicate the positions
of the respective proteins
apoptosis induction for 2102 EP showed that the apoptotic
response in this cell line was not simply delayed in time. The
dose-effect relationship between cisplatin concentration and
extent of apoptosis induction further demonstrated that 2102 EP
cells are resistant to cisplatin-induced apoptosis (Figure iB).
The proteolytic cleavage of PARP was studied by immunoblot-
ting using a PARP-specific MAb (C-2-10) that recognizes both
116-kDa PARP and the 85-kDa apoptosis-related cleavage
fragment. The 85-kDa proteolytic PARP fragment was readily
detected in cell lysates of cisplatin-treated NT2, NCCIT and S2
cultures, but not in the cell lysate of drug-treated 2102 EP cells
(Table 1). Figure 2A shows a representative Western blot to illus-
trate the presence and absence of the 85-kDa PARP fragment in
cisplatin-treated NCCIT cells and 2102 EP cells respectively. The
apparent absence of proteolytic cleavage of PARP in cisplatin-
treated 2102 EPcells confirmed the nuclearmorphology data. These
data on induction ofapoptosis by cisplatin are in agreement with the
MTT IC90 values. The cell lines NT2 and NCCIT, with the highest
sensitivity for cisplatin in the MTT assay [NT2, IC9 8.5 ± 4.4gM
(mean ± s.d.); NCCIT, 7.0 ± 0.3gM], are the most sensitive for
induction ofapoptosis. The S2 cell line (IC9 15.2 ± 3.0gM) takes an
intermediate position, while in the resistant 2102 EP cell line (IC9
27.2 ± 3.6gM) hardly any apoptosis could be detected.
As cisplatin resistance has been associated with reduced intra-
cellular accumulation, we quantitated the total intracellular Pt
levels ofthese TGCT cell lines immediately after cisplatin incuba-
tion (100 gM, 2 h). As shown in Table 1, NT2 and 2102 EP cells
accumulated about equal amounts of Pt, while these cell lines
showed a 3.2-fold difference in cisplatin sensitivity (MTT data).
Notably, the differences in accumulation were completely paral-
leled by similar differences in Pt-DNA adduct formation (Table 1).
The observed intracellular Pt levels and DNA platination in
chemosensitive NT2 and chemoresistant 2102 EP cells excluded
the possibility that increased efflux as a result of functional over-
expression of an ATP-dependent glutathione S-conjugate pump
. p53 (Ishikawa et al, 1994) accounted for the differential chemosensi-
tivity. Hill et al (1994) suggested that the hypersensitivity of
TGCTs might be related to a defective capacity to remove (repair)
Pt-DNA adducts. However, chemosensitive NT2 and chemoresis-
tant 2102 EP cells both removed about 40% ofthe Pt lesions from
4- Bax their genome within 8 h (data not shown), which indicates that the
capacity to remove Pt/DNA adducts is identical and not impaired
in these cell lines.
*-Bcl-2
Expression of p53, Bax and Bcl-2
We determined both the p53 gene status by sequence analysis of
the completep53 cDNA and the p53 response upon cisplatin treat-
ment to evaluate the role of p53 in drug-induced apoptosis in our
panel ofTGCT cell lines. The sequence data revealed that NT2, S2
and 2102 EP cells are homozygous for wt p53, whereas NCCIT
cells are hemizygous for p53 containing one mutated allele
carrying a 1-bp (G) deletion at position 949 of codon 272 (Table
1). The mutated p53 allele with a stop codon at position 1114
encodes a truncated p53 protein of 347 amino acids that migrates
faster than wt p53 protein (Figure 2B). This truncated p53 protein
lacks the carboxy terminus encompassing the tetramerization,
nuclear localization and DNA damage recognition site (Harris,
1996). The carboxy terminus of the p53 protein has been impli-
cated in the induction of apoptosis (Wang et al, 1996), but never-
theless we clearly demonstrated that mt p53 NCCIT and wt p53
NT2 cells are equally sensitive to drug-induced apoptosis.
Although no basal level of p53 protein was detected in S2 cells
(Figure 2B), despite the presence of p53 mRNA, drug-induced
apoptosis was evident (Figure 1). NT2 and 2102 EP cells express a
similar basal level of wt p53 protein, which was readily up-regu-
lated upon cisplatin treatment. In contrast, NCCIT and S2 cells
showed no cisplatin-induced p53 up-regulation. Consistent with
cisplatin-induced wt p53 up-regulation, only wt p53 protein of
NT2 and 2102 EP cells was capable to transactivate the
p21/WAF/CIP gene upon DNA damage (El-Deiry et al, 1993),
whereas mt p53-containing NCCIT cells and p53-non-expressing
S2 cells could nottransactivate this p53-responsive gene (Table 1).
Thus, NCCIT and S2 cells are apparently p53 transactivation defi-
cient, suggesting that there is no clear correlation between transac-
tivation-competent p53 and induction ofapoptosis in these TGCT
cell lines. Although our results show that the presence of func-
tional wt p53 is not required for cisplatin-induced apoptosis in
some TGCT cell lines (NCCIT and S2), it still can not be excluded
that wt p53 plays a role in the hypersensitivity of NT2 cells to
cisplatin. Studies on inactivation of p53 function by introduction
of the human papilloma virus E6 protein may serve to further
define the role ofp53 in TGCT cell lines. Our results concur with
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those of Cresta et al (1996), who concluded that the hypersensi-
tivity ofTGCT cell lines to etoposide-induced apoptosis was asso-
ciated with functional p53. However, it should be noted that all the
chemosensitive TGCT cell lines that they compared with chemo-
resistant bladder cancer cell lines contained wt p53, and in the
study presented here we compared TGCT cell lines that differ in
their p53 status.
The Bcl-2/Bax ratio is often an important determinant of apop-
tosis and determines the extent to which apoptosis is induced or
suppressed (Oltvai and Korsmeyer, 1994). Our immunoblotting
data, as presented in Figure 2B, reveal no correlation between
endogenous Bcl-2 and Bax protein levels and susceptibility to
drug-induced apoptosis. The endogenous levels of Bax protein in
our panel of TGCT cell lines were found to be similar. No Bcl-2
protein expression was found in NCCIT cells, whereas readily
detectable and similar Bcl-2 protein levels were found in the other
TGCT cell lines. In addition to the endogenous Bcl-2 and Bax
expression, which are inherent to the cell, we examined the effect
of different doses of cisplatin (3.1-12.5 tM) on the expression of
these death-modulating genes, which was monitored at different
time points after treatment (6-72 h). Notably, Bcl-2 and Bax
expression was not affected by cisplatin, irrespective of the dose
and time point studied (Figure 2B). With respect to Bax expression
as detected by Bax PAb, it should be noted that we found identical
results with a Bax MAb that became available only recently (data
not shown). Although no Bax up-regulation was apparent by
immunoblotting, we have demonstrated previously heterogeneous
Bax expression and up-regulation within the apoptotic NT2 popu-
lation using flow cytometry (Boersma et al, 1997). However, no
Bax up-regulation could be detected by flow cytometry in the
other TGCT cell lines (AWM Boersma, personal communication).
Our results indicate that the Bcl-2/Bax rheostat is probably not
involved in cisplatin-induced apoptosis ofTGCT cell lines.
In summary, our data suggest that, at least in our panel ofTGCT
cell lines, there seems to be no clear relationship between
cisplatin-induced apoptosis and (a) growth characteristics, (b)
cellular Pt accumulation, (c) DNA platination, (d) Pt-DNA adduct
removal, (e) p53 status, (f) intrinsic Bcl-2 and Bax expression and
(g) cisplatin-induced modulation of the Bcl-2/Bax ratio. The
observed lack of correlation between p53 status and apoptosis
induction may indicate that the presence of wt p53 is not
absolutely required for the successful treatment ofTGCTs. Further
unraveling of the apoptotic pathway and identification of key
determinants of chemosensitivity in TGCTs may lead to more
appropriate and successful anti-cancer treatment modalities for
tumour types that are now considered to be drug resistant.
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